Patent intelligence · US
US 11497815
Muscle targeting complexes and uses thereof for treating dystrophinopathies
Muscle targeting complexes and uses thereof for treating dystrophinopathies
Patent details — US 11497815
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 15, 2022
- Expiration
- Nov 10, 2042
- Applicant
- Dyne Therapeutics, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K31/713, A61K47/10
Quick answer
US 11497815 (Muscle targeting complexes and uses thereof for treating dystrophinopathies) is held by Dyne Therapeutics, Inc.. Status: granted. Granted Nov 15, 2022. Expires Nov 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Dyne Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K31/713, A61K47/10, A61K47/549, A61K47/6807
More from Dyne Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428487
Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject
granted -
US 12403203
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 12397062
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 12370264
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
granted -
US 12357703
Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping
granted -
US 12329824
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 12329825
Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject
granted -
US 12325753
Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy
granted
Frequently asked questions
What is US patent 11497815?
US 11497815 (Muscle targeting complexes and uses thereof for treating dystrophinopathies) is held by Dyne Therapeutics, Inc.. Status: granted. Granted Nov 15, 2022. Expires Nov 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11497815?
Dyne Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 82 pharmaceutical patents for this assignee.
When does US 11497815 expire?
Our index shows an expiration date of Nov 10, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.